Dr. Katsunori Nonogaki is currently working as a Professor in the Department of Diabetes Technology, Tohoku University Graduate School of Biomedical Engineering, Japan. He has obtained PhD in Endocrinology, Metabolism, and Diabetes from Nagoya University Graduate School of Medicine, Japan. He found the novel evidence in the dissociated pathways of serotonin 5-HT2C receptor and leptin in the central regulation of appetite and obesity, and proposed a novel physiological theory of “Central dissociated regulation of feeding and autonomic neural circuits”. Lorcaserin (Belviq), a selective 5-HT2C receptor agonist, which is used for the treatment of obesity, is based on the original research works carried by him. Current studies are to determine the physiological mechanisms and potential treatment for obesity, diabetes and their complications. He is a member of many professional organizations and also acting as Editorial board member and reviewer for several peer reviewed journals.